P&G Board Seat Swings To Peltz In Ongoing Vote Tally
Executive Summary
P&G says results from an independent tabulator indicate Trian Fund head Nelson Peltz is leading the firm's candidate, Ernesto Zedillo, in a board proxy vote by around 42,780 shares, or 0.0016% of total outstanding shares. But P&G says the vote count isn't completed.
You may also be interested in...
US Q3 Consumer Health Earnings Preview: Coming Changes Overshadow Current Conditions?
Rather than reflecting what’s coming in the way of spinoffs, leadership, product approvals or deal closings, firms’ July-September results will reveal influences from inflation and supply chain problems. Like manufacturers across industries, US consumer health product firms are dealing with US currency strengthening and potentially driving down revenues through losses in foreign exchange.
Moeller Takes P&G Reins With 33-Year Grasp Of Products, Planning And Footprint
Jon Moeller appointed to succeed David Taylor, at the helm for almost six years and remaining as executive chairman, a day before P&G releases FY21 full-year and Q4 results.
P&G Adds Merck's Brands, Expands Consumer Health Categories, Footprint
P&G’s planned purchase of Merck KGaA’s consumer health care business will grow its personal health portfolio 50%, expand its OTC drug and supplement business abroad and open up new categories. CEO David Taylor framed the acquisition as another step in the firm's ongoing portfolio shakeup.